Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Genentech announces two Phase III study results of Lucentis

Genentech announces two Phase III study results of Lucentis

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Enrollment for pSivida's pilot FAVOR clinical study commences

Enrollment for pSivida's pilot FAVOR clinical study commences

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Aston Academy investigates macular oedema

Aston Academy investigates macular oedema

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration